Table 1.
HSC and MSC transplantation characteristics
| Diagnoses | ALL-10, JMML-2, XLP-2, AML-15; AML/MDS-7, NHL-4, WAS-1, OP-1, SCID-1, CML-2, CLL-2, SAA-1, MM-1, SCD-1 |
| Age | Median 19 (1 to 69) |
| (children-25, adults-25) | |
| Gender M:F | 28:22 (56%:44%) |
| HSC matching (n=50) | MFD-12 |
| MUD-25 | |
| 9/10-7 | |
| 8/10-2 | |
| haplo-2 | |
| UCB-2 | |
| MSC matching (n=74) | 3rd party, full mismatched-62 |
| 3rd party, haplo-5 | |
| Same donor, haplo-2 | |
| Same donor, matched-5 | |
| aGVHD development | d+9 to d+150 |
| aGVHD severity (maximal) | grade IV-42 |
| grade II-III-8 | |
| Number of systems involved | One-9 |
| Two-18 | |
| More-21 | |
| Other treatments | MP (regular ± high dose)-50, CsA-50, tacrolimus-40, rapamycin-8, MMF-40, ATG-27, anti-CD25 mAb-9, ECP-16 |
| MSC delivery | i.v. only-72 |
| i.a. + i.v.-2 | |
| Average first MSC dose | 1.05 (0.3 to 2.25) x10E6 per kg |
Abbreviations: ALL - acute lymphoblastic leukemia; AML - acute myeloid leukemia; ATG - antithymocyte globulin (Fresenius or Thymoglobulin); CLL - chronic lymphocytic leukemia; CML - chronic myeloid leukemia; ECP - extracorporeal photopheresis; i.a. - intra-arterial injection; i.v. - intravenous; JMML - juvenile myelomonocytic leukemia; MDS - myelodysplastic syndrome; MFD - matched family donor; MM - multiple myeloma; MMF - mycophenolate mofetil; MP - methyl prednisolone; MUD - matched unrelated donor; NHL - non-Hodgkin’s lymphoma; OP - osteopetrosis; SAA - severe aplastic anemia; SCD - sickle cell disease; SCID - severe combined immune deficiency; UCB - umbilical cord blood; WAS - Wiscott Aldrich Syndrome; XLP - X-linked lymphoproliferative disease.